Australia markets closed
  • ALL ORDS

    7,426.60
    +76.00 (+1.03%)
     
  • AUD/USD

    0.7005
    -0.0028 (-0.39%)
     
  • ASX 200

    7,182.70
    +70.20 (+0.99%)
     
  • OIL

    113.95
    +1.55 (+1.38%)
     
  • GOLD

    1,812.10
    -6.80 (-0.37%)
     
  • BTC-AUD

    42,085.14
    -1,720.52 (-3.93%)
     
  • CMC Crypto 200

    660.17
    -10.51 (-1.57%)
     

Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00AM ET on January 10th through the following link: https://journey.ct.events/view/d2cd046c-ff2c-40ea-acdc-340df7150783 and on Lumos Pharma’s website in the Investors & Media section under “Events & Presentations.” This webcast will be archived for 90 days on the Company’s website.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting